Telix Pharmaceuticals Ltd (TLX) ADR EACH REPR SPON

Sell:$15.80Buy:$16.86$1.58 (11.04%)

NASDAQ:12.16%
Market closed | Prices delayed by at least 15 minutes
Sell:$15.80
Buy:$16.86
Change:$1.58 (11.04%)
Deal now
Market closed | Prices delayed by at least 15 minutes
Sell:$15.80
Buy:$16.86
Change:$1.58 (11.04%)
Market closed | Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. It is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Its segments include Therapeutics, Precision Medicine and Telix Manufacturing Solutions. Therapeutics segment develops targeted radionuclide therapies for urologic, neurologic, musculoskeletal and hematological cancers. Precision Medicine segment focuses on bringing diagnostic imaging solutions to market. Precision Medicine segment also includes MedTech and International businesses. Telix Manufacturing Solutions segment is its global network of facilities designed to deliver patient doses worldwide. Its pipeline products include TLX591, TLX250, TLX101, TLX66, TLX592, TLX252, TLX400, Illuccix (68Ga-PSMA-11) and TLX007-CDx.

Key people

Christian P. Behrenbruch
Group Chief Executive Officer, Managing Director, Executive Director
Darren Smith
Group Chief Financial Officer
Raphaeel Ortiz
Chief Executive Officer - Telix International
Kevin Richardson
Chief Executive Officer - Telix Precision Medicine
Darren Patti
Group Chief Operating Officer
Paul Schaffer
Chief Technology Officer
Lena Moran-Adams
Group General Counsel
David Cade
Group Chief Medical Officer
James Stonecypher
Group Chief Development Officer
Richard Valeix
Group Chief Commercial Officer
H. Kevin Mccann
Non-Executive Independent Chairman of the Board
Marie McDonald
Non-Executive Director
Anne C. Whitaker
Non-Executive Director
Mark Nelson
Non-Executive Independent Director
Tiffany P. Olson
Non-Executive Independent Chairman of the Board
Click to see more

Key facts

  • EPIC
    TLX
  • Location
    Australia
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US87961M1053
  • Market cap
    $0.00
  • Employees
    234
  • Shares in issue
    334.73m
  • Exchange
    Australian Stock Exchange Ltd
  • Index
    ASX All Ordinaries Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.